Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced late-breaking data from the Phase III OCARINA II study. Study results demonstrate the effect of Ocrevus® (ocrelizumab) as an investigational twice-yearly, 10-minute subcutaneous injection on pharmacokinetic, biomarker, and MRI measures in patients with relapsing or primary progressive multiple sclerosis (RMS or PPMS). The data will be presented in a poster at the 9t.

Genentech's Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions

Roche (RHHBY) Vabysmo maintains vision improvements with extended treatment intervals of up to four months in phase III studies for retinal vein occlusion.

Roche's (RHHBY) Vabysmo Positive in Late-Stage RVO Studies

Basel, 10 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline long-term results from the global phase III BALATON and COMINO studies, evaluating extended treatment intervals with Vabysmo® (faricimab) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO).1,2

Roche's Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive topline long-term results from the global Phase III BALATON and COMINO studies evaluating extended treatment intervals with Vabysmo® (faricimab-svoa) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO). From weeks 24 to 72, all people in both studies received Vabysmo using a treat-and-extend dosing regimen, which allows tailori.

Genentech's Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials

Ambev

Adyen NV

Bayer AG

British American Tobacco

Anheuser-Busch InBev

Diageo

FANUC Corp

GlaxoSmithKline

Imperial Brands PLC

JD.com

Medtronic

Novozymes A/S

Omron Corp

Safran SA

Shimano Inc

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analysis.

International Wide-Moat Stocks On Sale - The October 2023 Heat Map

Basel, 04 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented positive results from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic SMA (n=26), aged from birth to six weeks. The data were presented at the 28th World Muscle Society (WMS) Congress, 3-7 October 2023.

Majority of newborn babies with spinal muscular atrophy (SMA) treated with Roche's Evrysdi able to sit independently after 1 year of treatment

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today presented positive results from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic SMA (n=26), aged from birth to 6 weeks. These data were presented at the 28th World Muscle Society (WMS) Congress, October 3-7, 2023. “Evrysdi is the only non-invasive SMA treatment and can be used withi.

Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech's Evrysdi Able to Sit Independently After 1 Year of Treatment

RIO RANCHO, N.M.--(BUSINESS WIRE)--NTx has appointed Marcel Roche as Chief Financial Officer to guide financial strategy and drive growth.

Nature's Toolbox Appoints Marcel Roche as Chief Financial Officer

Basel, 02 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new data for OCREVUS® (ocrelizumab) and investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib for multiple sclerosis (MS), and ENSPRYNG® (satralizumab) for neuromyelitis optica spectrum disorder (NMOSD). In total, Roche will be presenting 36 abstracts at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Research in Multiple Sclerosis) from 11-13 October 2023. Late-breaking data in MS includes the Phase Ib OCARINA I and Phase III OCARINA II studies evaluating an investigational subcutaneous OCREVUS injection. In addition, the Phase II FENopta study of fenebrutinib for people living with MS and late-breaking ENSPRYNG data for people with NMOSD, which includes longer-term data from the Phase III SAkuraMoon study, will also be presented.

Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will present new data for Ocrevus® (ocrelizumab) and investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib for multiple sclerosis (MS), and Enspryng® (satralizumab) for neuromyelitis optica spectrum disorder (NMOSD). In total, Genentech will be presenting 36 abstracts at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Resear.

Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD

Pakistan's drug regulator said on Monday it had temporarily banned the use of a cancer medication distributed by Swiss pharmaceutical company Roche pending an investigation, as 12 patients went blind after being injected with the drug.

Pakistan bans Roche cancer drug pending probe into patients' blindness

Roche has optionality to grow its pipeline with selective M&A and new partnerships. The company also confirmed better pharmaceutical growth expectations. We evaluated the three biggest readouts, Elevidys, TIGIT, and Inavolisib, providing supportive news. From a premium valuation to a discount vs. its closest peers. We believe this is not justified. Our buy rating is confirmed.

Roche: Positive Readouts From Pipeline

Roche's stock price has declined, underperforming its peers, due to the loss of patent protection for its blockbuster drugs, lower Covid-related revenue and several pipeline setbacks. The company has developed second-generation drugs and expanded into new therapeutic areas to offset the decline in revenue. 2023 is expected to be a challenging year for Roche, but revenue is projected to grow again in 2024 and beyond.

Roche: 2023 Should Mark The Bottom

Alnylam Pharmaceuticals

BridgeBio Pharma Inc

The pharmaceutical industry is one of the most dynamic and innovative sectors in the world. It is constantly developing new drugs and treatments to address various health challenges and improve the quality of life of millions of people.

Buy List Alert: 3 Pharma Stocks with Positive Trial Updates

Roche is open to making big acquisitions if they make "sense", Chief Executive Thomas Schinecker said, with the Swiss drugmaker unencumbered by its $20.7 billion deal last year to buy back its shares from Novartis.

Roche open to big acquisitions 'if it makes scientific and financial sense' - CEO tells newspaper

Sanofi

Tencent Holdings Limited

Taiwan Semiconductor Manufacturing

Yum China Hlds

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for.

International Wide-Moat Stocks On Sale - The September 2023 Heat Map

Basel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT), met the primary endpoint. Zilebesiran demonstrated a clinically significant reduction in 24-hour mean systolic blood pressure (SBP) at month three, achieving a placebo-subtracted reduction greater than 15 mmHg with both 300 and 600 mg doses (p < 0.0001). The study also met key secondary endpoints showing consistent and sustained reductions of SBP at six months supporting quarterly or biannual dosing. In addition, the study showed that zilebesiran was associated with a potent and durable reduction of serum AGT levels through month six while demonstrating an encouraging safety and tolerability profile.

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease

A new form of accounting that more accurately reflects the impact a company has on the planet and society is essential, the executive said.

Impact accounting 'urgently' needed - Roche's Hoffmann

Roche (RHHBY) biologics license application seeking approval for crovalimab for paroxysmal nocturnal hemoglobinuria gets FDA acceptance.

Roche's (RHHBY) Application for PNH Drug Accepted by FDA

DALLAS--(BUSINESS WIRE)--CyrusOne, a leading global data center developer and operator, specializing in delivering state-of-the-art digital infrastructure solutions, today announced the promotion of Jim Roche to Senior Vice President of Engineering. In this role, Roche will lead CyrusOne's engineering development team, overseeing engineering and design services including power and usage projections, floor planning, connectivity assessments and implementation scheduling . Roche most recently ser.

CyrusOne Promotes Jim Roche to Senior Vice President of Engineering

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) for crovalimab, an investigational, novel anti-C5 recycling monoclonal antibody, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The acceptance was based on results from the pivotal Phase III COMMODORE 2 study, which demonstrated that in pe.

FDA Accepts Application for Genentech's Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition

The report shows digital health technologies demonstrate value, yet integrating them into care systems remains challenging. Involving healthcare professionals and patients in technology design and development is also critical for patient-centred care.1 The report surveyed 10 countries, all of which have some foundations in place to use digital health technologies, such as regulatory frameworks and interoperability standards.

Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare

Roche's (RHHBY) late-stage ALK-positive non-small cell lung cancer study evaluating Alecensa meets the primary endpoint of disease-free survival.

Roche's (RHHBY) Late-Stage Lung Cancer Study Meets Primary Goal

Basel, 01 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III ALINA study evaluating Alecensa® (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) at a prespecified interim analysis. Alecensa demonstrated a statistically significant and clinically meaningful improvement in DFS as adjuvant therapy in people with completely resected stage IB (tumour ≥4cm) to IIIA (UICC/AJCC 7th edition) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Alecensa is the first and only ALK inhibitor to demonstrate a reduction in the risk of disease recurrence or death for people with early-stage ALK-positive NSCLC in a Phase III trial.

Roche's Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III ALINA study evaluating Alecensa® (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) at a prespecified interim analysis. Alecensa demonstrated a statistically significant and clinically meaningful improvement in DFS as adjuvant therapy in people with completely resected Stage IB (tumor ≥.

News for Roche Holding AG Stock (RHHBY)